Grace Therapeutics
GRCE
14 hedge funds and large institutions have $1.55M invested in Grace Therapeutics in 2017 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 1 closing their positions.
610% more capital inflows, than outflows
Capital inflows: $1.78M | Capital outflows: $251K
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
27% more funds holding
Funds holding: 11 → 14 (+3)
7.28% more ownership
Funds ownership: 3.57% → 10.85% (+7.3%)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$784K |
| 2 |
Renaissance Technologies
New York
|
+$375K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$354K |
| 4 |
Virtu Financial
New York
|
+$176K |
| 5 |
Morgan Stanley
New York
|
+$55K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$245K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$5.44K |
| 3 |
Intact Investment Management
Montreal,
Quebec, Canada
|
-$672 |
| 4 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$134 |
GRCE Hedge Fund Activity: Q4 2017 in Review
14 of the 4,420 institutional investors tracked by Wall St. Rank reported a position in Grace Therapeutics (GRCE) for Q4 2017, worth a combined $1.55M — up 99% from $778K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new GRCE positions and 1 closed out — a net gain of 3 holders — while 3 added to existing stakes and 3 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $784K. The largest seller was Bank of Montreal, cutting an estimated $245K.
- 14 institutional investors held Grace Therapeutics (GRCE) as of Q4 2017, up from 11 in Q3 2017.
- Funds reported $1.55M of Grace Therapeutics stock for Q4 2017, up 99% quarter-over-quarter.
- 4 funds opened new Grace Therapeutics positions in Q4 2017 and 1 closed out, a net change of +3 holders.
- The largest Grace Therapeutics buyer in Q4 2017 was Susquehanna International Group, an estimated $784K added.
- The largest Grace Therapeutics seller in Q4 2017 was Bank of Montreal, an estimated $245K sold.
Based on aggregated 13F filings for Q4 2017.